Media coverage about Catalyst Pharmaceuticals (NASDAQ:CPRX) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Catalyst Pharmaceuticals earned a news impact score of 0.13 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 47.3929252829257 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several analysts have recently commented on the company. BidaskClub cut Catalyst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, March 16th. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, March 15th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $6.25.
Shares of CPRX traded down $0.07 during trading hours on Friday, hitting $2.55. 111,864 shares of the stock traded hands, compared to its average volume of 664,953. Catalyst Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $4.51. The firm has a market capitalization of $254.34, a PE ratio of -12.29 and a beta of 1.62.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). equities analysts predict that Catalyst Pharmaceuticals will post -0.36 EPS for the current fiscal year.
In other news, insider Patrick J. Mcenany purchased 20,000 shares of the business’s stock in a transaction dated Tuesday, April 3rd. The shares were acquired at an average price of $2.29 per share, with a total value of $45,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 9.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://transcriptdaily.com/2018/04/13/catalyst-pharmaceuticals-cprx-earning-somewhat-positive-press-coverage-analysis-finds.html.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.